`
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________
`
`STEADYMED LTD.
`
`Petitioner,
`
`v.
`
`UNITED THERAPEUTICS CORPORATION
`
`Patent Owner.
`
`
`
`Case IPR 2016-00006
`
`Patent No. 8,497,393B2
`
`____________
`
`PETITIONER’S MOTION FOR SUPPLEMENTAL INFORMATION
`UNDER 37 C.F.R. § 42.123
`
`
`
`
`Mail Stop "Patent Board"
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`
`1
`
`
`
`Petitioner SteadyMed Ltd. (“Petitioner”) hereby moves for leave to submit
`
`supplemental information pursuant to 37 C.F.R. § 42.123. On a conference call
`
`between the parties dated May 10, 2016, the PTAB panel provided authorization
`
`for Petitioner to file this motion. Furthermore, it is noted that Patent Owner’s
`
`representative, Steve Maebius, who was on the conference call, indicated that he
`
`did not oppose the filing of this motion. The present motion seeks to submit
`
`Exhibit 1019 and Exhibit 1020 which are supplemental declarations attesting to the
`
`accuracy of the English translation of Japanese Patent Application No. 56-
`
`122328A, “Crystalline Amine Salt of Methanoprostacyclin Derivative,
`
`Manufacturing Method Thereof, and Purifying Method Thereof,” referred to as
`
`“Kawakami.”
`
`I.
`
`The Present Motion Complies with the Rules
`
`The present motion complies with the requirements of 37 C.F.R. § 42.123.
`
`First, the Board instituted the above-identified inter partes review in a Decision
`
`dated April 8, 2016. (Paper 12). Petitioner timely made a request for the
`
`authorization to file a motion to submit supplemental information within one
`
`month of the date trial was instituted, on Friday, May 6, 2016, pursuant to 37
`
`C.F.R. § 42.123(a)(1). Second, the Decision in the present inter partes review
`
`relies on Kawakami as a key reference for invalidating at least one claim. As such,
`
`Kawakami is relevant to a claim for which the trial has been instituted, pursuant to
`
`
`
`2
`
`
`
`37 C.F.R. § 42.123(a)(2).
`
`II. The Requested Supplemental Information
`
`As mentioned above, the present inter partes review refers to and relies on
`
`Kawakami for invalidating at least one claim. Exhibit 1006 refers to the original,
`
`Japanese language version of Kawakami, and Exhibit 1007 refers to the certified
`
`English translation of Kawakami. With its petition, Petitioner submitted Exhibit
`
`1011, a declaration attesting to the accuracy of the English translation of
`
`Kawakami, from Mr. Boris Levine, president, owner, and chief Japanese translator
`
`at Technical Language Services, Inc. Mr. Levine, who is fluent in Japanese and
`
`English, oversaw and personally checked the English translation of Kawakami that
`
`one of his employees, Mr. James Dowdle, created. Patent Owner, however,
`
`objected to Mr. Levine’s declaration (Exhibit 1007) because “there is no evidence
`
`that the translator Boris Levine has personal knowledge of the translation of
`
`Kawakami in Exhibit 1007 or even that he knows how to translate any document
`
`from Japanese to English.” (Paper 20, Patent Owner’s Objections to Petitioner’s
`
`Evidence).
`
`Petitioner seeks to submit two declarations: (1) Exhibit 1019 is a
`
`supplemental declaration from Mr. Levine, who served as check translator of
`
`Kawakami; and (2) Exhibit 1020 is a declaration from Mr. Dowdle, who
`
`performed the English translation of Kawakami. Both declarations certify that Mr.
`
`
`
`3
`
`
`
`Levine and Mr. Dowdle are fluent in both Japanese and English, the English
`
`translation is true and correct, and satisfies all of the formalities of 37 C.F.R. §
`
`1.68. Petitioner submits that the English translation of Kawakami as provided in
`
`the originally filed Exhibit 1007 has not been changed, and notes, similar to the
`
`Board, that Patent Owner has not presently identified any error with the translation
`
`that would call into question its authenticity.
`
`As additional grounds for granting this motion, Petitioner directs the Board
`
`to Taiwan Semiconductor v. DSS Technology Management, Inc., IPR No. 2014-
`
`01030 (Paper 11, p. 3), where the Board, on nearly identical facts, granted a similar
`
`motion, and held that the supplemental information Petitioner sought "to submit
`
`does not change the grounds of unpatentability authorized in this proceeding, nor
`
`does it change the evidence initially presented in the Petition to support those
`
`grounds of patentability. Instead, such information merely constitutes additional
`
`evidence that allegedly confirms the accuracy of the English translation …."
`
`Accordingly, and for the reasons set forth above, Petitioner asks that the
`
`Board accept this motion.
`
`
`
`
`
`Date: May 11, 2016
`
`
`/s Stuart E. Pollack /
`Stuart E. Pollack, J.D. Ph.D.
`Reg. No. 43,862
`DLA Piper LLP (US)
`
`
`
`Respectfully submitted,
`
`/s Lisa A. Haile / __________
`Lisa A. Haile, J.D., Ph.D.
` Reg. No. 38,347
`DLA Piper LLP (US)
`
`4
`
`
`
`
`
`The undersigned certifies
`
`the attached Motion for
`
`CERTIFICATE OF SERVICE
`
`that a copy of
`
`Supplemental Information was served via electronic mail to the following:
`
`Stephen B. Maebius
`George Quillin
`FOLEY & LARDNER LLP
`UT393-IPR@foley.com
`
`Shaun R. Snader
`UNITED THERAPEUTICS CORP.
`ssnader@unither.com
`
`Douglas Carsten
`Richard Torczon
`Robert Delafield
`WILSON, SONSINI, GOODRICH & ROSATI
`dcarsten@wsgr.com
`rtorczon@wsgr.com
`bdelafield@wsgr.com
`
`
`
`
`/s Lisa A. Haile /
`Lisa A. Haile, J.D., Ph.D.
`Reg. No. 38,347
`DLA Piper LLP (US)
`
`
`
`
`
`Date: May 11, 2016
`
`
`/s Stuart E. Pollack /
`Stuart E. Pollack, J.D., Ph.D.
`Reg. No. 43,862
`DLA Piper LLP (US)
`
`
`
`
`
`5